Thermo Fisher Scientific Quarterly Cash Flow Statement
NYSE: TMOIndustrialsIndustrial Machinery/ComponentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Thermo Fisher Scientific free cash flow
In the quarter ended Jun 27, 2026, Thermo Fisher Scientific generated $2.13 billion of operating cash flow and spent $450.0 million on capital expenditures. That left free cash flow of $1.68 billion, a free-cash-flow margin of 14.0% of revenue. Free cash flow was up 51.6% from the prior year's $1.10 billion.
Thermo Fisher Scientific returned $1.18 billion to shareholders: $175.0 million in dividends and $1.00 billion in share repurchases, equal to 70% of free cash flow. Free cash flow covered dividend payments 9.6 times.
Summary generated from market data by MetaCap's automated system. Methodology
Thermo Fisher Scientific cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-27 | Q1 20262026-03-28 | Q4 20252025-12-31 | Q3 20252025-09-27 | Q2 20252025-06-28 | Q1 20252025-03-29 | Q4 20242024-12-31 | Q3 20242024-09-28 | Q2 20242024-06-29 | Q1 20242024-03-30 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.74B | 1.66B | 1.97B | 1.62B | 1.62B | 1.51B | 1.82B | 1.63B | 1.55B | 1.33B | 1.61B | 1.70B |
| Net Income growth (YoY) | +7.60% | +9.60% | +8.00% | -0.49% | +4.19% | +13.52% | +13.57% | -3.89% | +14.02% | +3.02% | +2.03% | +13.15% |
| Depreciation & Amortization | 331.00M | 306.00M | 292.00M | 227.00M | 256.00M | 276.00M | 304.00M | 291.00M | 276.00M | 285.00M | 276.00M | 269.00M |
| Stock-Based Compensation | 82.00M | 83.00M | 84.00M | 70.00M | 81.00M | 75.00M | 79.00M | 68.00M | 84.00M | 70.00M | 61.00M | 67.00M |
| Operating Cash Flow | 2.13B | 1.19B | 3.46B | 2.24B | 1.40B | 723.00M | 3.29B | 2.17B | 1.96B | 1.25B | 3.72B | 2.41B |
| Capital Expenditures | -450.00M | -376.00M | -465.00M | -404.00M | -294.00M | -362.00M | -480.00M | -272.00M | -301.00M | -347.00M | -405.00M | -332.00M |
| Investing Cash Flow | 164.00M | -8.96B | 891.00M | -4.12B | -288.00M | -527.00M | 20.00M | -3.58B | -253.00M | -2.03B | -376.00M | -1.18B |
| Dividends Paid | -175.00M | -162.00M | -162.00M | -163.00M | -162.00M | -149.00M | -149.00M | -150.00M | -149.00M | -135.00M | -136.00M | -135.00M |
| Share Repurchases | -1.00B | -3.00B | -37.00M | -963.00M | 0 | -2.00B | -1.00B | 0 | 0 | -3.00B | 0 | 0 |
| Debt Issued | 0 | 5.24B | 4.92B | 0 | 0 | 2.84B | 0 | 0 | -1.00M | 1.21B | 2.48B | 3.47B |
| Debt Repaid | 0 | -1.41B | -787.00M | 0 | -787.00M | -838.00M | -2.50B | -1.11B | 0 | 0 | -3.78B | -1.00B |
| Financing Cash Flow | -1.57B | 1.09B | 3.53B | -632.00M | -991.00M | -102.00M | -3.67B | -1.19B | -115.00M | -1.82B | -1.43B | 1.85B |
| Net Change in Cash | 817.00M | -6.60B | 7.87B | -2.59B | 431.00M | 132.00M | -630.00M | -2.43B | 1.58B | -2.58B | 1.93B | 3.02B |
| Free Cash Flow | 1.68B | 816.00M | 2.99B | 1.83B | 1.10B | 361.00M | 2.81B | 1.89B | 1.66B | 904.00M | 3.32B | 2.08B |
This table shows 12 quarterly periods of Thermo Fisher Scientific's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TMO's reporting calendar. What is a cash flow statement?